FORTRESS BIOTECH INC (FBIO) Fundamental Analysis & Valuation

NASDAQ:FBIO • US34960Q3074

Current stock price

2.42 USD
+0.07 (+2.98%)
At close:
2.34 USD
-0.08 (-3.31%)
Pre-Market:

This FBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. FBIO Profitability Analysis

1.1 Basic Checks

  • In the past year FBIO has reported negative net income.
  • In the past year FBIO has reported a negative cash flow from operations.
  • FBIO had negative earnings in each of the past 5 years.
  • FBIO had a negative operating cash flow in each of the past 5 years.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • With an excellent Return On Assets value of -1.01%, FBIO belongs to the best of the industry, outperforming 87.02% of the companies in the same industry.
  • FBIO has a Return On Equity of -3.78%. This is amongst the best in the industry. FBIO outperforms 88.76% of its industry peers.
Industry RankSector Rank
ROA -1.01%
ROE -3.78%
ROIC N/A
ROA(3y)-26.92%
ROA(5y)-25.3%
ROE(3y)-184.73%
ROE(5y)-164.27%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

1.3 Margins

  • FBIO has a better Gross Margin (66.92%) than 79.26% of its industry peers.
  • In the last couple of years the Gross Margin of FBIO has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for FBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.07%
GM growth 5Y-0.32%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. FBIO Health Analysis

2.1 Basic Checks

  • FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FBIO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, FBIO has more shares outstanding
  • The debt/assets ratio for FBIO has been reduced compared to a year ago.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -5.63, we must say that FBIO is in the distress zone and has some risk of bankruptcy.
  • FBIO's Altman-Z score of -5.63 is on the low side compared to the rest of the industry. FBIO is outperformed by 65.12% of its industry peers.
  • A Debt/Equity ratio of 1.19 is on the high side and indicates that FBIO has dependencies on debt financing.
  • FBIO has a worse Debt to Equity ratio (1.19) than 76.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.19
Debt/FCF N/A
Altman-Z -5.63
ROIC/WACCN/A
WACC11.12%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M -150M

2.3 Liquidity

  • FBIO has a Current Ratio of 2.49. This indicates that FBIO is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of FBIO (2.49) is worse than 69.96% of its industry peers.
  • FBIO has a Quick Ratio of 2.30. This indicates that FBIO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of FBIO (2.30) is worse than 71.32% of its industry peers.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 2.3
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. FBIO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 73.09% over the past year.
  • The Revenue has grown by 9.69% in the past year. This is quite good.
  • Measured over the past years, FBIO shows a small growth in Revenue. The Revenue has been growing by 6.77% on average per year.
EPS 1Y (TTM)73.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.67%
Revenue 1Y (TTM)9.69%
Revenue growth 3Y-5.82%
Revenue growth 5Y6.77%
Sales Q2Q%6.34%

3.2 Future

  • The Earnings Per Share is expected to grow by 93.66% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, FBIO will show a very strong growth in Revenue. The Revenue will grow by 57.99% on average per year.
EPS Next Y101.16%
EPS Next 2Y93.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.34%
Revenue Next 2Y40.76%
Revenue Next 3Y108.71%
Revenue Next 5Y57.99%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

2

4. FBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FBIO. In the last year negative earnings were reported.
  • FBIO is valuated quite expensively with a Price/Forward Earnings ratio of 237.25.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of FBIO indicates a rather cheap valuation: FBIO is cheaper than 88.18% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 37.96. FBIO is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 237.25
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • FBIO's earnings are expected to grow with 93.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y93.66%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FBIO Dividend Analysis

5.1 Amount

  • FBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FBIO Fundamentals: All Metrics, Ratios and Statistics

FORTRESS BIOTECH INC

NASDAQ:FBIO (4/13/2026, 8:24:02 PM)

Premarket: 2.34 -0.08 (-3.31%)

2.42

+0.07 (+2.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-31
Earnings (Next)05-13
Inst Owners18.23%
Inst Owner Change-0.87%
Ins Owners15.69%
Ins Owner Change11.66%
Market Cap77.92M
Revenue(TTM)63.26M
Net Income(TTM)-1.88M
Analysts82.5
Price Target10.97 (353.31%)
Short Float %17.54%
Short Ratio5.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.02
Dividend Growth(5Y)-54.94%
DP-35.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.38%
Min EPS beat(2)-108.91%
Max EPS beat(2)125.68%
EPS beat(4)2
Avg EPS beat(4)-3.62%
Min EPS beat(4)-108.91%
Max EPS beat(4)125.68%
EPS beat(8)5
Avg EPS beat(8)5.73%
EPS beat(12)7
Avg EPS beat(12)12.24%
EPS beat(16)9
Avg EPS beat(16)9.47%
Revenue beat(2)0
Avg Revenue beat(2)-28.76%
Min Revenue beat(2)-39.76%
Max Revenue beat(2)-17.76%
Revenue beat(4)2
Avg Revenue beat(4)-8.99%
Min Revenue beat(4)-39.76%
Max Revenue beat(4)10.85%
Revenue beat(8)2
Avg Revenue beat(8)-13.9%
Revenue beat(12)5
Avg Revenue beat(12)2.77%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)100.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 237.25
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 3.5
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)0.01
Fwd EY0.42%
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS1.96
BVpS1.55
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.01%
ROE -3.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.92%
FCFM N/A
ROA(3y)-26.92%
ROA(5y)-25.3%
ROE(3y)-184.73%
ROE(5y)-164.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.07%
GM growth 5Y-0.32%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 1.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.49
Quick Ratio 2.3
Altman-Z -5.63
F-Score4
WACC11.12%
ROIC/WACCN/A
Cap/Depr(3y)140.15%
Cap/Depr(5y)110.94%
Cap/Sales(3y)10.67%
Cap/Sales(5y)8.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.67%
EPS Next Y101.16%
EPS Next 2Y93.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.69%
Revenue growth 3Y-5.82%
Revenue growth 5Y6.77%
Sales Q2Q%6.34%
Revenue Next Year49.34%
Revenue Next 2Y40.76%
Revenue Next 3Y108.71%
Revenue Next 5Y57.99%
EBIT growth 1Y36.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.97%
OCF growth 3YN/A
OCF growth 5YN/A

FORTRESS BIOTECH INC / FBIO Fundamental Analysis FAQ

What is the fundamental rating for FBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to FBIO.


What is the valuation status of FORTRESS BIOTECH INC (FBIO) stock?

ChartMill assigns a valuation rating of 2 / 10 to FORTRESS BIOTECH INC (FBIO). This can be considered as Overvalued.


What is the profitability of FBIO stock?

FORTRESS BIOTECH INC (FBIO) has a profitability rating of 2 / 10.


What is the earnings growth outlook for FORTRESS BIOTECH INC?

The Earnings per Share (EPS) of FORTRESS BIOTECH INC (FBIO) is expected to grow by 101.16% in the next year.